Novartis continues generics expansion
the recently expanded European Union, Switzerland's Novartis has
unveiled a €70 million overall investment in a new generics
production and logistics facility in Strykow, Poland.
Operated by Slovenia generics leader Lek, acquired by Novartis' generics subsidiary Sandoz in 2002, the new facility will include an administration building, laboratories, production lines and storage centers.
Paul Choffat, chief executive of Novartis Consumer Health,said that the new site will produce generic medicines for use throughout Poland and across Europe.
Initially focused on the production of oral solid formulations of generic medicines including Ketonal (ketoprofen), Amlopin (amlodipine), Lovastatinum (lovastatin) and Altacet (aluminium acetate), the plant is expected to reach a production capacity of 1.5 billion tablets and capsules in the first year.
Export production is estimated at 10 per cent in the first year of operation, rising to as much as 20 per cent thereafter, according to Novartis.
Earlier this year, Sandoz unveiled another new production facility in Austria, as well as a plant for biopharmaceuticals production in Slovenia.
